[go: up one dir, main page]

ECSP14027694A - Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido - Google Patents

Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido

Info

Publication number
ECSP14027694A
ECSP14027694A ECIEPI201427694A ECPI201427694A ECSP14027694A EC SP14027694 A ECSP14027694 A EC SP14027694A EC IEPI201427694 A ECIEPI201427694 A EC IEPI201427694A EC PI201427694 A ECPI201427694 A EC PI201427694A EC SP14027694 A ECSP14027694 A EC SP14027694A
Authority
EC
Ecuador
Prior art keywords
methods
chelate complex
compositions
polypeptides
oligonucleotide chelate
Prior art date
Application number
ECIEPI201427694A
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14027694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of ECSP14027694A publication Critical patent/ECSP14027694A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describe una composición farmacéutica que contiene un complejo de quelato de oligonucleótido y al menos un polipéptido o polipéptido pegilado. La presente descripción también describe composiciones farmacéuticas adicionales y métodos para el tratamiento de enfermedades que incluyen infecciones virales.
ECIEPI201427694A 2012-05-18 2014-11-18 Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido ECSP14027694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30

Publications (1)

Publication Number Publication Date
ECSP14027694A true ECSP14027694A (es) 2015-12-31

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201427694A ECSP14027694A (es) 2012-05-18 2014-11-18 Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido

Country Status (34)

Country Link
US (1) US9492506B2 (es)
EP (1) EP2849798B1 (es)
JP (1) JP2015517504A (es)
KR (1) KR102068109B1 (es)
CN (1) CN104349793B (es)
AU (1) AU2013262416B2 (es)
BR (1) BR112014028654A2 (es)
CA (1) CA2873529C (es)
CL (1) CL2014003134A1 (es)
CO (1) CO7131387A2 (es)
CR (1) CR20140527A (es)
CY (1) CY1124345T1 (es)
DK (1) DK2849798T3 (es)
DO (1) DOP2014000264A (es)
EA (1) EA035967B1 (es)
EC (1) ECSP14027694A (es)
ES (1) ES2873844T3 (es)
HR (1) HRP20210840T1 (es)
HU (1) HUE054875T2 (es)
IL (1) IL235548B (es)
LT (1) LT2849798T (es)
MX (1) MX346239B (es)
MY (1) MY168778A (es)
NZ (1) NZ703095A (es)
PH (1) PH12014502551B1 (es)
PL (1) PL2849798T3 (es)
PT (1) PT2849798T (es)
RS (1) RS62030B1 (es)
SG (1) SG11201407599SA (es)
SI (1) SI2849798T1 (es)
SM (1) SMT202100319T1 (es)
TW (1) TWI635864B (es)
WO (1) WO2013170386A1 (es)
ZA (1) ZA201408674B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2158316E (pt) 2007-05-11 2015-07-20 Adynxx Inc Expressão génica e dor
WO2013170086A2 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
SG11201501255PA (en) 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
KR20170029577A (ko) * 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
SG11202104636XA (en) * 2018-11-08 2021-06-29 Aligos Therapeutics Inc S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
CA2498777C (en) * 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
ATE416789T1 (de) * 2003-10-27 2008-12-15 Vertex Pharma Kombinationen für die hcv-behandlung
CA2584207A1 (en) * 2004-10-19 2006-04-27 Replicor, Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US7776818B2 (en) * 2005-09-29 2010-08-17 S-Cell Biosciences, Inc. Methods to treat T-cell disorders using TISF
EP1942911A4 (en) * 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2009076679A2 (en) * 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR20120095397A (ko) * 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
HUE029521T2 (en) * 2010-08-20 2017-03-28 Replicor Inc Oligonucleotide chelate complexes
SG11201501255PA (en) 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
MX346239B (es) 2017-03-13
PH12014502551B1 (en) 2019-10-11
MX2014014021A (es) 2015-02-10
MY168778A (en) 2018-12-04
CO7131387A2 (es) 2014-12-01
EP2849798B1 (en) 2021-04-07
SI2849798T1 (sl) 2021-08-31
CL2014003134A1 (es) 2015-02-13
PL2849798T3 (pl) 2021-10-18
ES2873844T3 (es) 2021-11-04
AU2013262416B2 (en) 2017-05-11
EA201401278A1 (ru) 2015-04-30
SMT202100319T1 (it) 2021-09-14
DK2849798T3 (da) 2021-05-31
WO2013170386A1 (en) 2013-11-21
AU2013262416A1 (en) 2014-12-18
CY1124345T1 (el) 2022-07-22
IL235548A0 (en) 2015-01-29
PH12014502551A1 (en) 2015-01-21
KR20150013309A (ko) 2015-02-04
HRP20210840T1 (hr) 2021-08-06
US9492506B2 (en) 2016-11-15
CN104349793A (zh) 2015-02-11
PT2849798T (pt) 2021-05-18
IL235548B (en) 2019-07-31
ZA201408674B (en) 2016-01-27
CN104349793B (zh) 2017-11-10
HK1204279A1 (zh) 2015-11-13
EP2849798A4 (en) 2016-03-09
DOP2014000264A (es) 2015-01-31
CA2873529A1 (en) 2013-11-21
BR112014028654A2 (pt) 2017-10-10
KR102068109B1 (ko) 2020-01-21
TWI635864B (zh) 2018-09-21
NZ703095A (en) 2016-07-29
CA2873529C (en) 2020-08-18
US20130309201A1 (en) 2013-11-21
JP2015517504A (ja) 2015-06-22
RS62030B1 (sr) 2021-07-30
LT2849798T (lt) 2021-08-10
SG11201407599SA (en) 2014-12-30
TW201408308A (zh) 2014-03-01
EA035967B1 (ru) 2020-09-07
CR20140527A (es) 2014-12-15
EP2849798A1 (en) 2015-03-25
HUE054875T2 (hu) 2021-10-28

Similar Documents

Publication Publication Date Title
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CR20170060A (es) Anticuerpos anti tigit
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112014025041B8 (pt) Composição farmacêutica
DOP2016000253A (es) Nuevos compuestos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
IN2014CN00572A (es)
BR112014013972A8 (pt) inibidores de hcv nssa
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
BR112015002979B8 (pt) Forma cristalina, e, composição farmacêutica
EA201491581A1 (ru) Везикулярные композиции
CO2017005759A2 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
CO2017005767A2 (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201501177A1 (ru) Фармацевтические композиции